MedPath

Simmerafil

Generic Name
Simmerafil

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 19, 2025

Simmerafil (TPN171H): A Comprehensive Report on its Pharmacology and Clinical Development

1. Executive Summary

Simmerafil, also identified by its investigational code TPN171H, is an orally bioavailable small molecule that functions as a potent and selective phosphodiesterase type 5 (PDE5) inhibitor.[1] The compound is currently in advanced stages of clinical development, primarily targeting two distinct therapeutic indications: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Key entities spearheading its development include Vigonvita Life Sciences and the Shanghai Institute of Materia Medica.[2] Clinical investigations for ED have progressed to Phase III, with a New Drug Application (NDA) reportedly under review in China, while for PAH, Simmerafil (TPN171H) has completed Phase IIa clinical trials, demonstrating encouraging effects on pulmonary hemodynamics.[2]

It is imperative to address a notable ambiguity concerning the nomenclature "Simmerafil." The vast majority of detailed scientific information available, including specific chemical identifiers such as CAS number 1229018-87-4 and PubChem CID 136197286, along with extensive clinical trial data, unequivocally pertains to Simmerafil (TPN171H) as a selective PDE5 inhibitor.[1] However, two research snippets [8] describe a compound also named "Simmerafil" but characterize it as a Janus Kinase (JAK) inhibitor intended for the treatment of autoimmune conditions like rheumatoid arthritis and psoriasis. These latter descriptions lack the specific chemical identifiers and depth of corroborating clinical data associated with TPN171H. Consequently, this report will focus exclusively on Simmerafil (TPN171H), the PDE5 inhibitor, for which substantial and consistent evidence is provided. This discrepancy highlights potential issues in early-stage drug nomenclature or database inconsistencies, emphasizing the value of precise investigational codes.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.